



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_277_26

You asked:

Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia]
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Apremilast [Otezla]
- Apremilast [Generic]
- Baricitinib [Olumiant]
- Bimekizumab [Bimzelx]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Filgotinib [Jyseleca]
- Golimumab [Simponi]
- Golimumab Biosimilar
- Guselkumab [Tremfya]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Rituximab [MabThera]
- Rituximab Biosimilars
- Sarilumab [Kevzara]
- Secukinumab [Cosentyx]
- Tocilizumab [Ro Actemra]
- Tocilizumab Biosimilars
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]
- Ustekinumab Biosimilar

Our response:

Please find the patient numbers for the selected preparations below. The preparations were issued between February 2026 and April 2026, which is the most recent months for which data can be provided.

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The

data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.

Drug	Patient No.
Abatacept [Orencia]	58
Adalimumab [Humira]	43
Adalimumab Biosimilars	526
Apremilast [Otezla]	0
Apremilast [Generic]	9
Baricitinib [Olumiant]	36
Bimekizumab [Bimzelx]	57
Certolizumab [Cimzia]	66
Etanercept [Enbrel]	22
Etanercept Biosimilars	240
Filgotinib [Jyseleca]	17
Golimumab [Simponi]	58
Golimumab Biosimilar	0
Guselkumab [Tremfya]	**
Infliximab [Remicade]	0
Infliximab Biosimilars	24
Ixekizumab [Taltz]	25
Risankizumab [Skyrizi]	0
Rituximab [MabThera]	0
Rituximab Biosimilars	48
Sarilumab [Kevzara]	7
Secukinumab [Cosentyx]	89
Tocilizumab [Ro Actemra]	105
Tocilizumab Biosimilars	**
Tofacitinib [Xeljanz]	7
Upadacitinib [Rinvoq]	46
Ustekinumab [Stelara]	**
Ustekinumab Biosimilar	16